Daiichi Sankyo and AstraZeneca Launch Phase 3 Trial for Datroway in High-Risk Urothelial Cancer — Daiichi Sankyo Company, Limited

Event summary

First patient dosed in TROPION-Urothelial04 Phase 3 trial evaluating Datroway® (datopotamab deruxtecan) plus rilvegostomig or Datroway monotherapy versus current standard of care in high-risk muscle invasive urothelial cancer (MIUC).
Trial will enroll approximately 915 patients across multiple sites in Asia, Europe, North America, Oceania, and South America.
Primary endpoint is disease-free survival (DFS) for the combination of Datroway and rilvegostomig versus standard of care.
Datroway is a TROP2-directed antibody drug conjugate (ADC) jointly developed by Daiichi Sankyo and AstraZeneca.

The big picture

The initiation of the TROPION-Urothelial04 Phase 3 trial marks a strategic move by Daiichi Sankyo and AstraZeneca to expand the use of Datroway into earlier lines of treatment for high-risk urothelial cancer. This trial is part of a broader clinical development program evaluating Datroway across multiple cancer types, reflecting the companies' focus on leveraging ADC technology to address significant unmet needs in oncology. The trial's global scope and the inclusion of a novel combination therapy with rilvegostomig highlight the potential for differentiated treatment approaches in a disease area with limited approved TROP2-directed therapies.

What we're watching

Clinical Efficacy: Whether the combination of Datroway and rilvegostomig can demonstrate superior disease-free survival compared to current standard of care.
Regulatory Pathway: The pace at which positive trial results could lead to regulatory approvals for Datroway in urothelial cancer.
Market Competition: How Daiichi Sankyo and AstraZeneca will position Datroway against existing and emerging therapies in the urothelial cancer space.